Poseida Therapeutics
(NASDAQ:PSTX)
$3.0789
-0.0011[-0.04%]
At close: Mar 27
$3.0789
0[0.00%]
PreMarket: 7:00PM EDT
Consensus Rating1
Buy
Highest Price Target1
$40.00
Lowest Price Target1
$10.00
Consensus Price Target1
$20.50

Poseida Therapeutics Stock (NASDAQ:PSTX), Analyst Ratings, Price Targets, Predictions

Poseida Therapeutics Inc has a consensus price target of $20.5, established from looking at the 15 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Piper Sandler, and HC Wainwright & Co. on March 8, 2024, December 11, 2023, and December 11, 2023. With an average price target of $16.67 between HC Wainwright & Co., Piper Sandler, and HC Wainwright & Co., there's an implied 441.32% upside for Poseida Therapeutics Inc from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Oct 23
1
Dec 23
2
Mar
1
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Piper Sandler
Cantor Fitzgerald
HC Wainwright & Co.
Cantor Fitzgerald

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Poseida Therapeutics

date
▲▼
ticker
▲▼
Buy Now
Company
▲▼
Current price
▲▼
Upside/Downside
▲▼
Analyst Firm
▲▼
Analyst & % Accurate
▲▼
Price Target Change
▲▼
Rating Change
▲▼
Previous / Current Rating
▲▼
Get Alert
03/08/2024PSTXBuy Now
Poseida Therapeutics
$3.08549.58%HC Wainwright & Co.
Arthur He
→ $20ReiteratesBuy → BuyGet Alert
12/11/2023PSTXBuy Now
Poseida Therapeutics
$3.08224.79%Piper Sandler
Edward Tenthoff
$8 → $10MaintainsOverweightGet Alert
12/11/2023PSTXBuy Now
Poseida Therapeutics
$3.08549.58%HC Wainwright & Co.
Arthur He
$15 → $20MaintainsBuyGet Alert
10/10/2023PSTXBuy Now
Poseida Therapeutics
$3.08354.71%Cantor Fitzgerald
Jennifer Kim
→ $14ReiteratesOverweight → OverweightGet Alert
08/08/2023PSTXBuy Now
Poseida Therapeutics
$3.08387.19%HC Wainwright & Co.
Arthur He
→ $15ReiteratesBuy → BuyGet Alert
05/23/2023PSTXBuy Now
Poseida Therapeutics
$3.08387.19%HC Wainwright & Co.
Arthur He
→ $15ReiteratesBuy → BuyGet Alert
05/10/2023PSTXBuy Now
Poseida Therapeutics
$3.08387.19%HC Wainwright & Co.
Arthur He
→ $15Reiterates → BuyGet Alert
03/10/2023PSTXBuy Now
Poseida Therapeutics
$3.08387.19%HC Wainwright & Co.
Arthur He
→ $15Reiterates → BuyGet Alert
02/23/2023PSTXBuy Now
Poseida Therapeutics
$3.08387.19%HC Wainwright & Co.
Arthur He
→ $15MaintainsBuyGet Alert
02/01/2023PSTXBuy Now
Poseida Therapeutics
$3.08679.5%Cantor Fitzgerald
Jennifer Kim
→ $24Reiterates → OverweightGet Alert
01/04/2023PSTXBuy Now
Poseida Therapeutics
$3.08387.19%HC Wainwright & Co.
Swayampakula Ramakanth
→ $15Initiates → BuyGet Alert
08/09/2022PSTXBuy Now
Poseida Therapeutics
$3.08257.27%Piper Sandler
Edward Tenthoff
$9 → $11MaintainsOverweightGet Alert
05/13/2022PSTXBuy Now
Poseida Therapeutics
$3.08192.31%Piper Sandler
Edward Tenthoff
$19 → $9MaintainsOverweightGet Alert
01/07/2022PSTXBuy Now
Poseida Therapeutics
$3.08679.5%Cantor Fitzgerald
Brian Cheng
→ $24Initiates → OverweightGet Alert
05/18/2021PSTXBuy Now
Poseida Therapeutics
$3.081199.17%BTIG
Justin Zelin
—Initiates → BuyGet Alert

FAQ

Q

What is the target price for Poseida Therapeutics (PSTX)?

A

The latest price target for Poseida Therapeutics (NASDAQ: PSTX) was reported by HC Wainwright & Co. on March 8, 2024. The analyst firm set a price target for $20.00 expecting PSTX to rise to within 12 months (a possible 549.58% upside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Poseida Therapeutics (PSTX)?

A

The latest analyst rating for Poseida Therapeutics (NASDAQ: PSTX) was provided by HC Wainwright & Co., and Poseida Therapeutics reiterated their buy rating.

Q

When was the last upgrade for Poseida Therapeutics (PSTX)?

A

There is no last upgrade for Poseida Therapeutics.

Q

When was the last downgrade for Poseida Therapeutics (PSTX)?

A

There is no last downgrade for Poseida Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Poseida Therapeutics (PSTX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Poseida Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Poseida Therapeutics was filed on March 8, 2024 so you should expect the next rating to be made available sometime around March 8, 2025.

Q

Is the Analyst Rating Poseida Therapeutics (PSTX) correct?

A

While ratings are subjective and will change, the latest Poseida Therapeutics (PSTX) rating was a reiterated with a price target of $0.00 to $20.00. The current price Poseida Therapeutics (PSTX) is trading at is $3.08, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch